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ABSTRACT The lack of information regarding the mechanisms of action (MoA) or
speciﬁc molecular targets of phenotypically active compounds can prove a barrier to
their development as chemotherapeutic agents. Here, we report the results of our
orthogonal genetic, molecular, and biochemical studies to determine the MoA of a
novel 7-substituted 8-hydroxy-1,6-naphthyridine (8-HNT) series that displays promis-
ing activity against Trypanosoma brucei and Leishmania donovani. High-throughput
loss-of-function genetic screens in T. brucei highlighted two probable zinc transport-
ers associated with resistance to these compounds. These transporters localized to
the parasite Golgi apparatus. Directed by these ﬁndings, the role of zinc and other
divalent cations in the MoA of these compounds was investigated. 8-HNT com-
pounds were found to directly deplete intracellular levels of Zn2, while the addi-
tion of exogenous Zn2 and Fe2 reduced the potency of compounds from this se-
ries. Detailed biochemical analyses conﬁrmed that 8-HNT compounds bind directly
to a number of divalent cations, predominantly Zn2, Fe2, and Cu2, forming 2:1
complexes with one of these cations. Collectively, our studies demonstrate transition
metal depletion, due to chelation, as the MoA of the 8-HNT series of compounds.
Strategies to improve the selectivity of 8-HNT compounds are discussed.
KEYWORDS chelator, drug discovery, kinetoplastids, mechanisms of action,
transition metals
The protozoan parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmaniaspp. are the causative agents of the human infections sleeping sickness, Chagas’
disease, and leishmaniasis, respectively. These diseases are responsible for more than
74,000 fatalities annually and the loss of over 4,600,000 disease-adjusted life years (1).
Some of the poorest areas of the world are afﬂicted by these vector-borne parasites,
and the accompanying economic burden provides a major obstacle to improving
human health (2). There are no approved therapeutic vaccines, and current treatments
for protozoan diseases suffer from a range of problems, including severe toxicity and
emerging drug resistance (3–5). To compound these difﬁculties, many of the current
chemotherapeutic treatments require lengthy periods of hospitalization and are pro-
hibitively expensive (2). Thus, there is an urgent need for better, safer, efﬁcacious drugs
that are ﬁt for purpose in resource-poor settings.
Antitrypanosomatid drug discovery has been hindered by a paucity of robustly
validated drug targets in these parasites (6). This has severely limited target-focused
screening programs and has increased reliance upon phenotypic screening of parasites
to identify start points for drug discovery. Phenotypic approaches, involving the
screening of compounds directly against intact parasites in in vitro culture, have proven
effective (7). However, a lack of information regarding the mechanism(s) of action
(MoA) or speciﬁc molecular target(s) of these active compounds can often prove a
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barrier to their optimization in order to overcome pharmacokinetic and/or toxicity
issues. A more complete understanding of MoA can also facilitate the prioritization of
compounds with novel and promising targets or the deprioritization of compounds
with known unattractive or failed targets, such as sterol 14-demethylase (CYP51) in T.
cruzi (8, 9). Furthermore, such knowledge can inform future drug combination strate-
gies and may identify novel mechanisms that could be exploited de novo for target-
based drug discovery.
Here, we describe orthogonal genetic, molecular, and biochemical studies focused
on determining the MoA of a novel 7-substituted 8-hydroxy-1,6-naphthyridine (8-HNT)
series that displayed promising activity against T. brucei and Leishmania donovani. This
compound series emerged from screening a 1.8-million-compound library against L.
donovani as part of a collaboration between GlaxoSmithKline (GSK) and the University
of Dundee Drug Discovery Unit (10). Our comprehensive MoA studies reveal that 8-HNT
compounds chelate transition metals and that this chelation forms the basis of their
cytotoxicity in protozoan parasites.
RESULTS
Identiﬁcation and development of an antitrypanosomal 8-HNT series. Screen-
ing of GSK’s 1.8-million-compound library against L. donovani axenic amastigotes,
followed by secondary screening of “hits” in a L. donovani intramacrophage assay,
identiﬁed a total of 351 active compounds comprised of 33 compound series and 75
singletons (10). One of these active compounds, an 8-hydroxy naphthyridine (TCMDC-
143180) (compound 1) (Fig. 1), demonstrated reasonable potency against both the
mammalian (intracellular amastigotes) (50% effective concentration [EC50], 2.1 M) and
insect (promastigote) (EC50, 0.76 M) stages of L. donovani. In addition, compound 1
was also active against T. brucei (bloodstream form) (EC50, 0.32 M) while demonstrat-
ing limited activity against mammalian cell lines (THP-1 or HepG2) (Fig. 1).
Based upon these promising ﬁndings, and the fact that related 8-hydroxyquinoline
derivatives have already been shown to demonstrate some moderate activity against
both L. donovani and T. cruzi (11, 12), compound 1 was used as a start point for
subsequent medicinal chemistry. The principal aims driving compound development
were to improve potency, selectivity against HepG2 cells, and aqueous solubility. As a
result, compounds 2 and 3 were developed, with both compounds demonstrating
improved activity against L. donovani in an intramacrophage assay although similar
FIG 1 Chemical structures and activities of three 8-HNT compounds. Chemical structures of 8-HNT compound 1
(DDD01007886) (TCMDC-143180; GSK1363355A), compound 2 (DDD01011700) (GSK3454797A), and compound 3
(DDD01012232) (GSK3454397A) are shown. Potencies of compounds against L. donovani promastigotes (pro), L.
donovani intramacrophage amastigotes, T. brucei bloodstream forms (bsf), THP-1 cells, and HepG2 cells are shown;
data are from 3 independent replicates.
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levels of activity against T. brucei (Fig. 1). Full details of the medicinal chemistry leading
to the development of compounds 2 and 3 will be reported elsewhere.
Genome-wide RNAi screens reveal genes encoding putative cation transport-
ers. An understanding of the MoA or molecular targets of compounds can facilitate the
development of more potent and selective compounds. Our studies focused on deter-
mining the MoA of 8-HNT compounds in T. brucei and L. donovani. Genome-wide RNA
interference (RNAi) screens have proven highly effective in determining drug MoA
(13–15). Although these screens do not identify classical drug targets, this methodology
can identify drug resistance determinants in T. brucei that assist in the determination of
drug MoA. With this in mind, typically lethal concentrations of compounds 1 to 3
(equivalent to 2 to 3 the respective EC50s) were used to screen a genome-scale T.
brucei bloodstream-form RNAi library, and drug-resistant populations were then sub-
jected to RNAi target sequencing (RIT-seq) (16). During screening under tetracycline
induction, each trypanosome produces double-stranded RNA (dsRNA) from an inte-
grated RNAi target fragment, and the resulting target knockdown has the potential to
confer a growth advantage under drug selection. RIT-seq then generates a readout that
identiﬁes the RNAi target fragments responsible. High-throughput sequencing of the
selected populations following screens with compounds 1 to 3 provided between 2.1
million and 3.4 million paired-end reads, with 96 to 98% of reads mapping to the
reference genome (Fig. 2A; see also Tables S1 to S3 in the supplemental material). A
putative cation transporter (Tb927.11.15050) was identiﬁed as a prominent “hit” in all
three screens, while screening with compounds 1 and 2 identiﬁed a second putative
cation transporter (Tb927.11.1910) (Fig. 2B). Additional hits, principally from the screen
with compound 1, were identiﬁed, including glycosomal ABC transporter 3 (GAT3)
(Tb927.11.1070) (17) and subunits of the vacuolar-type H-ATPase (V-ATPase) (18)
(summarized in Tables S1 to S3).
To validate the role of the putative cation transporters, independent, inducible,
hairpin RNAi knockdown strains were generated for each transporter. Quantitative
real-time PCR (qRT-PCR) conﬁrmed that the transcript levels for both genes were
reduced by between 50 and 70% without growth defects (see Fig. S1 in the supple-
mental material). In addition, both native genes were tagged with C-terminal 12Myc
tags in the RNAi strains, and knockdown of the tagged proteins was demonstrated by
protein blotting (Fig. S1). Knockdown of Tb927.11.15050 led to a3-fold increase in the
EC50 for compound 1, while knockdown of Tb927.11.1910 resulted in no marked
change in sensitivity (EC50 of 0.6  0.05 M compared to 0.85  0.05 M for wild-type
[WT] trypanosomes) (Fig. 2C).
Tb927.11.15050 and Tb927.11.1910 encode Golgi-localized putative zinc trans-
porters. To gain insight into the function(s) of the two putative cation transporters,
phylogenetic and domain analyses of the proteins encoded by Tb927.11.15050 and
Tb927.11.1910 were undertaken. Amino acid sequence analysis predicted that both
proteins maintained 6 membrane-spanning domains (see Fig. S1 in the supplemental
material) and that both proteins were also closely related to a number of zinc trans-
porters, including the well-characterized human ZnT (zinc transporter) family (19). The
principal function of the ZnT family is to transport zinc out of the cytoplasm, in contrast
to the ZIP (ZRT, IRT-like protein) family of transporters that are responsible for zinc
uptake into the cytoplasm (19). The Tb927.11.15050-encoded protein was most closely
related to ZnT6, while the Tb927.11.1910-encoded protein was most closely related to
ZnT5 and ZnT7 (Fig. 3A). In human cells, ZnT5 to -7 are localized to the Golgi apparatus
and involved in the transport of zinc into the organelle (20, 21). Indeed, both the
Tb927.11.15050 and Tb927.11.1910 proteins fused with a C-Myc tag colocalized with
the Golgi marker GRASP (Golgi reassembly stacking protein) (22) in bloodstream
trypanosomes (Fig. 3B). Collectively, these data suggest that the proteins encoded by
Tb927.11.15050 and Tb927.11.1910 likely function as zinc transporters facilitating the
uptake of zinc into the Golgi apparatus.
Zn2 or Fe2 reduces the potency of 8-HNT compounds against T. brucei and
L. donovani. The data described above suggested that the depletion of zinc import to
Antitrypanosomal Divalent Transition Metal Chelators Antimicrobial Agents and Chemotherapy
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the Golgi apparatus reduced the efﬁcacy of the 8-HNT compounds against T. brucei.
Therefore, we hypothesized that 8-HNT compounds were reducing zinc levels in
trypanosomes; zinc transporter knockdown could reduce potency by increasing cyto-
plasmic zinc concentrations. To test this hypothesis, we added exogenous zinc to
parasites and asked whether this reduced the potency of the 8-HNT compounds. In the
ﬁrst instance, we established the level of ZnCl2 that could be added to T. brucei without
impacting cell growth and viability (200 M ZnCl2) (see Fig. S2 in the supplemental
material). Next, the EC50 for compound 1 was determined in the presence and absence
of 200 M ZnCl2. The addition of exogenous Zn2 led to an 8-fold decrease in the
potency of compound 1, with an EC50 of 2.8  0.1 M, compared to 0.36  0.09 M
in the absence of Zn2 (Fig. 4A). Similar zinc-dependent shifts in potency were
observed for all three 8-HNT compounds (Table 1). Notably, the Zn2-dependent
shifts in potency observed with 8-HNT compounds in T. brucei mimic the modula-
tion of potency of a known zinc chelator [N,N,N=,N=-tetrakis(2-pyridylmethyl)ethane-
1,2-diamine (TPEN)] (Fig. S2). Our culture medium is supplemented with 10% fetal
FIG 2 Genome-wide RNAi screening of 8-HNT compounds to identify putative cation transporters in T.
brucei. (A) Genome-wide map indicating RIT-seq hits from screening of compound 1. Multiple RIT-seq
fragments represent primary hits, indicated in green. Other loci with mapped reads are indicated in gray.
RPKM, reads per kilobase of transcript per million mapped reads. (B) Hits on individual genes (indicated in
green). Other protein-coding sequences are indicated as black bars. Red peaks, forward reads with RNAi
construct barcodes; blue peaks, reverse reads with RNAi construct barcodes; gray peaks, all other reads. (C)
Dose-response curves of compound 1 against uninduced () and induced (Œ) Tb927.11.15050 and
Tb927.11.1910 knockdown bloodstream trypanosomes. Results are the means  standard deviations of
data from three independent experiments.
Wall et al. Antimicrobial Agents and Chemotherapy
August 2018 Volume 62 Issue 8 e00235-18 aac.asm.org 4
 o
n
 Septem
ber 3, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
bovine serum (FBS), and it is well established that serum contains many proteins that
bind zinc and other metals (23). Therefore, it is likely that signiﬁcant amounts of Zn2
are required to saturate the metal binding capacity of these serum proteins prior to
impacting the potency of 8-HNT compounds.
The effect of other divalent cations (Ca2, Cu2, Fe2, Mg2, and Mn2) on the
potency of the 8-HNT analogues was also assessed in T. brucei (Table 1). The addition
of 10 M exogenous FeCl2 to culture medium, the highest concentration of Fe2
tolerated by bloodstream T. brucei parasites, led to considerable increases in the EC50s
of the three compounds. The most marked shift in potency was seen with compound
1, where the EC50 was increased from 0.22  0.01 M to 1.8  0.2 M (8-fold) in the
presence of FeCl2 (Fig. 4B). In contrast, the addition of tolerated levels of all other
divalent cations had little or no impact on the potency of 8-HNT compounds. As a
control, and as expected, the addition of exogenous divalent cations, including Fe2
and Zn2, failed to alter the potency of a speciﬁc ornithine decarboxylase inhibitor,
diﬂuoromethylornithine (DFMO), against T. brucei (Fig. S2).
8-HNT compounds demonstrated promising activity against both intramacrophage
(amastigote) and insect-stage (promastigote) L. donovani parasites. To determine if the
addition of exogenous zinc also shifted the potency of these compounds for L.
donovani, EC50s for all three 8-HNT analogues against promastigotes were determined
in the presence and absence of ZnCl2. The addition of 100 M Zn2 led to an 11-fold
reduction in the potency of compound 1 (Fig. 4C) and even larger shifts in the
potencies of compounds 2 and 3 (Table S4). Similarly, the addition of 100 M FeCl2
reduced the potency of 8-HNT compounds for L. donovani (Fig. 4D and Table S4). These
data suggest that 8-HNT compounds are likely to share similar MoA in both T. brucei
and L. donovani.
FIG 3 Putative cation transporters share homology with mammalian ZnT transporters and are localized
to the Golgi apparatus. (A) Phylogenetic analysis of the proteins encoded by Tb927.11.15050 and
Tb927.11.1910 and their relationship to members of the human ZnT zinc transporter family. (B) Myc tags
(12) were introduced to the C termini of each putative cation transporter (Tb927.11.15050 and
Tb927.11.1910). Tagged versions of these putative transporters (green) were found to colocalize with
GRASP (red), a known marker of the Golgi apparatus of bloodstream trypanosomes. Cells were also
stained with 4=,6-diamidino-2-phenylindole (DAPI). Bars, 5 m.
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8-HNT compounds deplete levels of intracellular Zn2. To further explore our
hypothesis that 8-HNT compounds reduce Zn2 levels in parasites, the cell-permeable
ﬂuorescent reporter reagent FluoZin-3 was used to monitor intracellular levels of Zn2
in the presence or absence of all three compounds. The ﬂuorescence-based assay was
FIG 4 ZnCl2 or FeCl2 protects parasites, and intracellular Zn2 levels are decreased in the presence of 8-HNT
compounds. (A and B) Dose-response curves of compound 1 in the presence (Œ) and absence () of ZnCl2 (A) or FeCl2
(B) in T. brucei bloodstream-form parasites. In the presence of ZnCl2 (200 M), EC50s shifted from 0.35  0.01 M to
2.8  0.12 M. In the presence of FeCl2 (10 M), EC50s shifted from 0.22  0.01 M to 1.8  0.18 M. (C and D)
Dose-response curves of compound 1 in the presence (Œ) and absence () of ZnCl2 (C) or FeCl2 (D) in L. donovani
promastigotes. In the presence of ZnCl2 (100 M), EC50s shifted from 0.76  0.008 M to 8.3  0.32 M. In the
presence of FeCl2 (100 M), EC50s shifted from 0.78  0.03 M to 1.6  0.05 M. All EC50s represent the means 
standard deviations from three independent experiments. (E and F) Intracellular measurement of zinc as a percentage
in T. brucei bloodstream parasites normalized to the dimethyl sulfoxide (DMSO) control (100%) (E) and intracellular
measurement of zinc as a percentage in L. donovani promastigotes normalized to the DMSO control (100%) (F). Levels
of intracellular zinc were measured by using the ﬂuorescent zinc reporter FluoZin-3 (ﬁnal concentration, 5 M), as
described in Materials and Methods, in the presence of the zinc chelator TPEN (8 M), exogenous ZnCl2 (100 M), or
compounds 1 to 3 (5 M). All values represent the means  standard errors of the means for at least 3 experiments.
Wall et al. Antimicrobial Agents and Chemotherapy
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responsive to gross changes in intracellular levels of zinc in T. brucei bloodstream forms
or L. donovani promastigotes, as demonstrated by the addition of exogenous ZnCl2
(100 M) or by the addition of the zinc chelator TPEN (8 M) (Fig. 4E). Like TPEN, the
addition of the 8-HNT compounds (5 M) resulted in a decrease in ﬂuorescence,
indicating a depletion of the intracellular levels of zinc in both parasites (Fig. 4E and F).
It should be noted that our EC50s determining parasite viability are measured over a
72-h period, while our intracellular zinc assays are carried out within a 30-min period.
Therefore, it is not possible to directly correlate the amounts of Zn depleted in these
assays with those in our viability assays.
Initial screening demonstrated that 8-HNT compounds are moderately toxic to
human THP-1 monocytes and HepG2 cells, providing a potentially tolerable therapeutic
window (Fig. 1). Our data thus far suggested that 8-HNT compounds impacted Zn2
and Fe2 levels in multiple protozoan parasites. Therefore, we investigated the possi-
bility that 8-HNT compounds could be similarly affecting mammalian cells. First, the
addition of 100 M ZnCl2 shifted the EC50 of compound 2 for HepG2 cells 7-fold, from
47.8 3.6 M to 318.9 22 M (see Fig. S3 in the supplemental material). Second, the
FluoZin-3-based assay showed that all three 8-HNT compounds deplete intracellular
levels of Zn2 in HepG2 cells (Fig. S3). These data strongly suggest that 8-HNT
compounds have a MoA involving the depletion of divalent cations within protozoan
and mammalian cells and potentially other cell types.
To determine whether 8-HNT compounds act by entering cells and directly deplet-
ing intracellular Zn2 or by sequestering extracellular Zn2 in media, the uptake of
compound 1 by L. donovani promastigotes was measured. Using ultraperformance
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), the uptake of com-
pound 1 (5 M) by mid-log-phase parasites was determined following 30-min incuba-
tions at 37°C and 4°C. At 37°C, compound 1 was found to accumulate within cells to
levels 296  69 times higher than those seen in the supernatant (equivalent Kp
[permeability coefﬁcient] values). In contrast, at 4°C, the accumulation of compound 1
in promastigotes was signiﬁcantly reduced, to levels 29  13 times higher than those
in supernatants. Collectively, these data suggest that 8-HNT compounds are likely to be
transported rather than to diffuse into cells and mediate their effects on intracellular
levels of Zn2 directly from within cells.
8-HNT compounds are divalent cation chelators. The potential for 8-HNT com-
pounds to bind directly to Zn2 in a cell-free environment was assessed. The tetrapo-
tassium salt of the FluoZin-3 reporter reagent was incubated in the presence of ZnCl2
(100 M) and either TPEN (10 M) or compounds 1 to 3 (1 to 100 M) (Fig. 5A). As
expected, the addition of TPEN resulted in a reduction in the level of ﬂuorescence,
consistent with direct competition with the FluoZin-3 probe for Zn2 binding by this
established zinc chelator. The addition of 8-HNT compounds 1 to 3 to the assay mixture
also resulted in a dose-dependent reduction in the level of ﬂuorescence, again signi-
fying direct competition with the probe for Zn2 binding (Fig. 5A). In contrast, the
control compound (DFMO) did not affect the ﬂuorescence levels, suggesting that it
does not bind to Zn2.
TABLE 1 EC50s for 8-HNT compounds against T. brucei in the presence and absence of divalent transition metalsa
Divalent
cation
Compound 1 Compound 2 Compound 3
Mean EC50 (M)  SD Shift
(fold)
Mean EC50 (M) SD Shift
(fold)
Mean EC50 (M) SD Shift
(fold)WT Plus cation WT Plus cation WT Plus cation
CaCl2 0.3 0.8 0.4 0.1 1.1 1.2 0.04 1.3 0.06 1.0 0.8 0.1 0.7 0.04 0.9
CuCl2 0.3 0.08 0.4 0.005 1.1 1.4 0.07 1.3 0.06 0.9 0.8 0.05 0.8 0.06 1.1
FeCl2 0.2 0.01 1.8 0.2 8.0 0.7 0.06 1.6 0.05 2.4 0.9 0.03 3.5 0.3 3.7
MgCl2 0.4 0.01 0.4 0.03 1.1 0.8 0.05 0.9 0.02 1.1 0.8 0.05 0.7 0.05 0.9
MnCl2 0.4 0.01 0.4 0.02 1.0 1.4 0.09 1.2 0.05 0.8 0.8 0.05 1.01 0.04 1.3
ZnCl2 0.4 0.01 2.8 0.1 8.0 0.8 0.05 15.6 0.7 19.7 0.5 0.03 6.3 0.2 12.0
aEC50s represent the means  standard deviations for at least 3 experiments.
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The data described above strongly suggest that 8-HNT compounds act principally as
chelators of Zn2 and Fe2. Thus, the formation of metal ion–8-HNT complexes was
investigated by using spectrophotometric wavelength scanning. Each 8-HNT com-
pound has a characteristic spectrum in the absence of divalent cations (Fig. 5B). The
addition of increasing concentrations of speciﬁc divalent cations alters this spectrum,
which is indicative of the formation of new metal ion–8-HNT complexes. Spectral
changes induced by the addition of increasing concentrations of zinc were character-
ized and quantiﬁed for compound 1 (see Fig. S4 in the supplemental material). The
addition of Zn2 resulted in an increase in the absorbance at 475 nm (Fig. S4),
conﬁrming that, as suspected, compound 1 forms a complex with Zn2. Plotting the
change in the absorbances at 475 nm for a ﬁxed concentration of compound 1 (50 M)
and increasing concentrations of Zn2 demonstrated that binding of Zn2 is saturable
at 25 M (Fig. S4), indicating a 2:1 complex of compound 1-Zn2.
The stoichiometry of the complexes formed between the three 8-HNT compounds
and Zn2 was further investigated by measuring the absorbance at speciﬁc wave-
lengths while changing the molar ratio of each 8-HNT compound to Zn2 (Fig. 5C to
E). This analysis is commonly referred to as Job’s plot (24). Changes of the absorption
at 475, 390, and 375 nm are indicative of cation complex formation with compounds
FIG 5 Characterization of Zn2 binding to 8-HNT compounds in a cell-free system. (A) Levels of zinc were
measured by using the ﬂuorescent zinc reporter FluoZin-3 salt (ﬁnal concentration, 5 M), as described in
Materials and Methods, in the presence of the zinc chelator TPEN (8 M), exogenous ZnCl2 (100 M), DFMO
(1, 10, and 100 M), or compounds 1 to 3 (1, 10, and 100 M). Data were normalized to Zn2 levels in the
presence of a DMSO control (100%). All values represent the means  standard errors of the means for 3
independent experiments. (B) UV-Vis spectra of 50 M compound 1 (red), compound 2 (green), and
compound 3 (blue). (C to E) Job’s plots of Δ absorbance at 475 nm for compound 1, 390 nm for compound
2, and 375 nm for compound 3 relative to ﬁxed molar ratios of compound to Zn2. The intercepts at molar
fractions of 0.34 for compound 1, 0.31 for compound 2, and 0.35 for compound 3, illustrated by dashed red
lines, are indicative of a 2:1 stoichiometry between 8-HNT compounds and Zn2, respectively. (F to H) The
Δ absorbance values at ﬁxed molar ratios of compound to cation of 0.33 were plotted for each 8-HNT
compound and a range of divalent cations (Cu2, Fe2, Mg2, Mn2, and Zn2).
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August 2018 Volume 62 Issue 8 e00235-18 aac.asm.org 8
 o
n
 Septem
ber 3, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
1 to 3, respectively. The speciﬁc absorbance at these wavelengths was determined and
plotted against the molar ratio of the compound/cation to determine complex stoi-
chiometry. Peaks of absorbance at these wavelengths were achieved with molar ratios
of compounds 1 to 3 to Zn2 of 0.34, 0.31, and 0.35, respectively. Since a molar ratio
of 0.33 indicates the formation of a 2:1 stoichiometric complex, the data are consistent
with all three 8-HNT compounds forming a 2:1 complex with Zn2. Similarly, this 2:1
stoichiometry was observed for all complexes formed between the 8-HNT analogues
and the other divalent cations tested (Fig. 5).
It is not possible to accurately calculate the binding afﬁnity (Kd [dissociation con-
stant]) for components of 2:1 complexes; however, Job’s plots can provide some
indication of the comparative strengths of binding between 8-HNT compounds and
different divalent cations (24). Here, the absorbance at a ﬁxed molar ratio of 0.33
(compound/cation) was measured and compared for each 8-HNT compound-cation
complex (Fig. 5F to H). This analysis revealed subtle differences in the binding prefer-
ences of 8-HNT analogues for speciﬁc divalent cations. However, all three 8-HNT
compounds formed complexes most readily with Cu2 and least effectively with Mg2.
In keeping with our above-described data, all three analogues also bound strongly to
Zn2 and Fe2. Based on the in vitro data described above, the strength of 8-HNT
binding to Cu2 was surprising. An explanation for why the addition of Cu2may have
failed to shift the potency of 8-HNT against T. brucei in vitro is presented below. In
conclusion, the cytotoxic effects of 8-HNT compounds are due to the chelation of
divalent cations.
DISCUSSION
Several lines of evidence presented here establish that 8-HNT compounds chelate
divalent cations, principally Cu2, Zn2, and Fe2, and that this chelation forms the
primary basis of their cytotoxicity in trypanosomatid parasites and mammalian cells.
First, RNAi knockdown of two putative cation transporters, closely related to human
ZnT transporters involved in the uptake of zinc into the Golgi apparatus, are associated
with resistance to 8-HNT analogues. Second, the addition of exogenous Zn2 and Fe2
reduces the potency of 8-HNT compounds for L. donovani, T. brucei, and HepG2 cells.
Third, 8-HNT compounds deplete intracellular levels of Zn2 in L. donovani and HepG2
cells. Finally, spectrophotometric wavelength scanning demonstrates that 8-HNT com-
pounds bind directly to Cu2, Zn2, and Fe2 to form a 2:1 stoichiometric complex
with these divalent cations.
The putative cation transporters linked to decreased susceptibility to 8-HNT com-
pounds in the RNAi screens are closely related to the mammalian ZnT family of
vesicular zinc transporters, which are primarily associated with Zn2 sequestration into
intracellular compartments (25) and, consequently, also act to lower Zn2 concentra-
tions in the cytoplasm (26). The putative transporters encoded by Tb927.11.15050 and
Tb927.11.1910 localize speciﬁcally to the Golgi apparatus of bloodstream trypano-
somes. Recent studies have demonstrated that the Golgi apparatus, alongside the
endoplasmic reticulum (ER), acidocalcisomes, and mitochondria, serves as an intracel-
lular zinc store (27, 28). Thus, the knockdown of Golgi-speciﬁc zinc importers likely leads
to an increase in the concentration of free zinc within the cytoplasm. Since the
cell-permeable zinc probe used in our studies merely allowed us to measure signiﬁcant
changes in total intracellular Zn2 levels, it was not possible to directly measure the
likely small changes in cytosolic Zn2 that may result from the knockdown of these
Golgi-localized Zn2 importers. In the presence of a chelator, decreased export to the
Golgi apparatus may act to protect essential zinc-dependent functions within the
cytoplasm. Indeed, the transcript levels of ZnT family members 5, 6, and 7, most closely
related to the transporters identiﬁed in this study, were signiﬁcantly reduced in THP-1
monocytes treated with the zinc chelator TPEN (29). An alternative mechanism of
resistance to chelators such as 8-HNT compounds would be to reduce the levels of
plasma membrane-localized ZnT1 homologues, principally responsible for the efﬂux
Antitrypanosomal Divalent Transition Metal Chelators Antimicrobial Agents and Chemotherapy
August 2018 Volume 62 Issue 8 e00235-18 aac.asm.org 9
 o
n
 Septem
ber 3, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
of zinc out of the cell. No such transporters were identiﬁed in our RNAi screens, and
subsequent genome analyses failed to identify ZnT1 homologues in T. brucei.
In an attempt to tease out additional mechanisms of resistance to 8-HNT analogues,
L. donovani promastigotes were exposed to stepwise increasing concentrations of
compound 2 over several months, with the rationale that resistance determinants could
be identiﬁed by whole-genome sequencing of the resistant population. However, over
a 9-month period, we could not develop any resistance to compound 2 in these
parasites. Our failure to develop resistance to this 8-HNT compound in L. donovani is
particularly noteworthy. In our experience over several years, generation of resistance
in L. donovani promastigotes in vitro is eminently achievable (30–33), and compound 2
represents our ﬁrst failure. This observation is entirely consistent with chelation as the
MoA of this compound, because the pleiotropic functions of zinc and iron within the
cell are likely to leave parasites unable to generate mutations capable of alleviating all
the effects of metal extraction from multiple protein targets.
Additional hits from our RNAi library screens included subunits of the V-ATPase.
V-ATPases are involved in the generation of a proton gradient required for the
ATP-dependent transport of Zn2 and Fe2 into organelles, including the Golgi appa-
ratus (34–37). It is tempting to suggest that this role in the sequestration of divalent
cations may explain the relationship between V-ATPase subunit knockdown and 8-HNT
resistance.
Our RNAi screens led us to focus on the link between 8-HNT compounds and effects
on zinc homeostasis; however, our subsequent studies clearly demonstrate that 8-HNT
compounds are also strong chelators of Fe2. Undoubtedly, Leishmania and T. brucei
have a considerable requirement for both cations. It is well established that changes in
iron availability have a strong inﬂuence on the growth and virulence of pathogens,
while iron deprivation by various means is an important component of the host’s
ﬁrst-line defense against infection (38). The zinc chelator TPEN has been shown to
inhibit L. donovani in vitro (39, 40). Those studies demonstrated that zinc depletion led
to increased levels of reactive oxygen species in TPEN-treated promastigotes. Metal
ions such as Zn2 and Fe2 play a key role in redox reactions; as a consequence,
chelation of metal ions can lead to elevated levels of oxidative stress. Several iron
chelators (41), including deferoxamine (42), have also been shown to inhibit the growth
of both L. donovani and T. brucei in vitro. Deferoxamine also inhibits the growth of L.
major in vitro but was never tested in vivo due to the accompanying cytotoxicity against
mammalian cells (43).
Our spectrophotometric wavelength scanning studies demonstrate that 8-HNT
analogues form 2:1 stoichiometric complexes with divalent cations (Fig. 6). The coor-
dination of metal ions by these compounds is very similar to the complexes formed
between 8-hydroxyquinolines and metals, and it is evident that 8-HNT compounds
FIG 6 Proposed structure of the 2:1 complex formed between 8-HNT compounds and Zn2.
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share a structural motif with this compound class (44). Collectively, our studies illustrate
that three 8-HNT analogues demonstrate subtle differences in their preferences for
binding speciﬁc divalent cations. Of particular note, this approach illustrated the
preference of 8-HNT compounds for binding Cu2. Copper is known to form highly
stable complexes with cysteine (45) and catalyzes the oxidation of cysteine (46).
Bloodstream trypanosomes are cultured in HMI9-T medium, which is known to contain
high levels of cysteine as well as bathocuproine, a copper chelator (47). It is highly likely
that the bolus of Cu2 added to our culture medium is rapidly reduced by reaction with
cysteine to Cu (48) and that the resulting Cu is then chelated by bathocuproine,
preventing Cu from entering the cell (49). Thus, while our cell-based data place the
chelation of Zn2 and Fe2 at the heart of the cytotoxicity of these compounds, we
cannot rule out the possibility that chelation of Cu2 may also play a signiﬁcant role.
The identiﬁcation of chelation as the main driver for cytotoxicity is likely to present
a signiﬁcant challenge for the chemotherapeutic development of this chemical series,
speciﬁcally maintaining the potency of 8-HNT compounds while ensuring a sufﬁcient
therapeutic window. As it stands, our best 8-HNT compounds maintain an 100-fold
therapeutic window; clearly, work will be required to improve selectivity. In the search
for strategies to treat metal overload diseases, there is growing interest in the devel-
opment of “prochelators” (50–52), molecules that have little afﬁnity for metal ions until
they undergo activation in response to speciﬁc stimuli. Activation generally involves the
removal of a protective moiety by stimuli such as enzyme activation, oxidative stress,
or reducing environments. Our present study joins several others in illustrating the
vulnerability of kinetoplastid parasites to metal ion depletion. In the future, it may be
possible to employ a prochelation strategy to develop potent and safe 8-HNT ana-
logues that are activated at the site of infection.
MATERIALS AND METHODS
8-HNT compounds. All 8-HNT test compounds were synthesized by medicinal chemists within the
GlaxoSmithKline and University of Dundee collaboration funded by the Wellcome Trust. Details of
chemical syntheses for compound 1 (TCMDC-143180), compound 2, and compound 3 will be provided
in a subsequent publication.
Compounds. All compounds were of the highest quality and are as follows: TPEN [N,N,N=,N=-
tetrakis(2-pyridylmethyl)ethylenediamine; Sigma], FluoZin-3 AM (ThermoFisher), FluoZin-3 tetrapotas-
sium salt (ThermoFisher), pluronic F-127 (ThermoFisher), Fluo-4 AM (ThermoFisher), probenecid
(ThermoFisher), and ionomycin (Sigma).
Cell lines and culture conditions. The clonal Leishmania donovani cell line LdBOB (derived from
MHOM/SD/62/1S-CL2D) was grown as promastigotes at 28°C, as described previously (53). Bloodstream-
form T. brucei MiTat 1.2 clone 221a and its derived subline, 2T1, were cultured at 37°C in the presence
of 5% CO2 in HMI9-T medium, as described previously (54). The human carcinoma HepG2 cell line was
grown at 37°C with 5% CO2 in minimal Eagle’s medium (MEM) with GlutaMAX (1; Sigma-Aldrich),
nonessential amino acids (Sigma-Aldrich), and 10% FBS. Human HepG2 and THP-1 cells used in this study
were ethically sourced from the ATCC.
In vitro drug sensitivity assays. L. donovani intramacrophage (7), HepG2 (55), T. brucei (56), and L.
donovani promastigote (57) compound sensitivity assays were carried out as described previously.
Human HepG2 and THP-1 cells used in these assays were provided by the ATCC. Data were processed
by using GRAFIT (version 5.0.4; Erithacus Software) and ﬁtted to a 2-parameter equation to obtain the
effective concentration inhibiting growth by 50% (EC50). Data are presented as the means of results from
at least two independent experiments.
RIT-seq screening, Illumina sequencing, and analysis. The RNAi library screens were performed as
described previously (16). Tetracycline induction (24 h) of genome-wide RNAi initiates the formation of
gene-speciﬁc dsRNAs, leading to target knockdown. The population is then screened with compounds
to identify parasites where speciﬁc RNAi target knockdown has conferred compound resistance. Se-
quencing (RIT-seq) is then used to generate a genome-wide readout from the compound-resistant
parasite population. Libraries were maintained under blasticidin (1 g ml1) and phleomycin (1 g ml1)
selection in 150 ml medium with a minimum of 2  107 cells. Following tetracycline (1 g ml1)
induction for 24 h, compound 1 (448 nM), compound 2 (1.8 M), and compound 3 (1.2 M) were added
to cultures at concentrations equivalent to 2 to 3 their respective EC50s. Cultures were supplemented
with fresh compound and tetracycline as required. Based on cell growth, concentrations of compounds
2 and 3 were increased during library selection to ﬁnal concentrations of 5 M and 3.6 M, respectively.
This increase in the compound concentration was required to ensure that the surviving parasite
population was truly resistant and not merely tolerating the presence of the compound(s). This step
ensures that “hits” identiﬁed in subsequent analyses are speciﬁcally related to resistance mechanisms.
DNA was extracted from compound-selected cells on days 8, 13, and 20 for compounds 1, 3, and 2,
respectively.
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RNAi target fragments were ampliﬁed from compound-selected parasites by PCR using the Lib2f and
Lib2r primers (16). For high-throughput identiﬁcation of fragments, the PCR products were fragmented
and sequenced by using an Illumina HiSeq platform at BGI (Beijing Genomics Institute). Reads were
mapped to the T. brucei 927 reference genome (v9.0; TriTrypDB [http://tritrypdb.org/]) with Bowtie 2
software (58), using the following parameter: very-sensitive-local-phred33. The subsequent alignment
ﬁles were manipulated with SAMtools (59) and a custom script to identify reads with barcodes
(GCCTCGCGA) (16). Total and barcoded reads were then quantiﬁed by using the Artemis genome
browser (60).
Phylogenetic analysis. Phylogenetic analysis of the proteins encoded by Tb927.11.1910 and
Tb927.11.15050 was performed by using NCBI protein blast. Sequences for the human ZnT proteins were
downloaded from the NCBI database and aligned by using ClustalX. A protein feature visualization tool,
Protter, was used to identify and display transmembrane domains (61).
Stem-loop RNAi and tagging vector construction. Stem-loop RNAi constructs were assembled as
described previously (54, 62). PCR primers were designed by using RNAit software (63). For HL2
(Tb927.11.15050), primers HL2FW and HL2RV were used to generate a 533-bp gene fragment, and for
HL3 (Tb927.11.1910), primers HL3FW and HL3RV were used to generate a 513-bp gene fragment. The
accuracy of all assembled constructs was veriﬁed by sequencing. Assembled constructs were linearized
by using AscI prior to transfection into bloodstream T. brucei 2T1 parasites (62). In addition to phleomycin
(1 g ml1), trypanosomes maintaining successfully integrated vectors were selected using hygromycin
(2.5 g ml1) and conﬁrmed to be puromycin (2 g ml1) resistant. To generate C-terminal 12Myc
tagging vectors for Tb927.11.15050 (Myc1) and Tb927.11.1910 (Myc2), primers Myc1FW and Myc1RV and
primers Myc2FW and Myc2RV were used to generate 924-bp and 1,095-bp fragments, respectively.
Fragments were inserted into the pNATx12xMyc construct (54) via HindIII and XbaI restriction sites. The
accuracy of the assembled constructs was veriﬁed by sequencing, and the constructs were linearized
with the restriction endonuclease MfeI prior to transfection into the above-described HL2 and HL3
trypanosomes. Trypanosomes maintaining successfully integrated vectors were selected with blasticidin
(1 g ml1).
qRT-PCR. RNA was isolated from T. brucei bloodstream-form parasites by using an RNeasy puriﬁca-
tion kit (Qiagen), and cDNA was synthesized by using a high-capacity RNA-to-cDNA kit (Applied
Biosystems). qRT-PCR mixtures consisted of 2 l (80 ng) cDNA, 10 l Brilliant III Ultra-Fast QPCR master
mix (Agilent Technologies), 1 l (500 nM) of the forward and reverse primers, 0.3 l (30 nM) of reference
dye, and nuclease-free water. Analysis was conducted by using an Agilent Mx3005P machine under the
following cycling conditions: 95°C for 3 min, 40 cycles of 95°C for 20 s, and then 60°C for 20 s. A reference
gene, TERT (telomerase reverse transcriptase) (Tb927.11.10190), was used to provide a baseline of
transcription levels to allow normalization of the data (64). Relative quantiﬁcation for the tetracycline-
induced RNAi knockdown cell lines was normalized to the value for the corresponding uninduced cell
line by using the ΔΔCT method. Two experimental clones were used, and Student’s unpaired t test was
used to show signiﬁcance.
Western blotting. T. brucei whole-cell extracts (1  106 parasites per lane) were prepared in sample
buffer (62 mM Tris [pH 6.8], 10% glycerol, 2.3% SDS, 5% 2-mercaptoethanol) in the absence of boiling,
separated by SDS-PAGE, and transferred onto nitrocellulose. After blocking with 5% skimmed milk in
phosphate-buffered saline (PBS) for 1 h, blots were incubated for 1 h in the presence of a mouse
monoclonal anti-Myc antibody (1:500; Source BioScience), and membranes were washed in PBS con-
taining 0.1% (vol/vol) Tween 20 and then incubated with a secondary antibody (rabbit anti-mouse IgG)
(1:10,000; Dako, UK). Immunoblots were developed by using the ECL (enhanced chemiluminescence)
plus system from GE Healthcare (Piscataway, NJ, USA).
Effect of divalent metals on the potency of 8-HNT compounds against T. brucei, L. donovani,
and HepG2 cells. In the ﬁrst instance, the maximum tolerated concentrations of ZnCl2, CaCl2, CuCl2,
MgCl2, MnCl2, and FeCl2 were determined for each cell type. For T. brucei, the maximum concentrations
of metal salt having a minimal impact on cell growth were as follows: 200 M ZnCl2, 3 mM CaCl2, 5 M
CuCl2, 1 mM MgCl2, 10 M MnCl2, and 10 M FeCl2. For L. donovani, promastigotes were able to tolerate
the addition of 100 M exogenous FeCl2 and ZnCl2. HepG2 cells tolerated the addition of 100 M
exogenous ZnCl2. Standard drug sensitivity assays were carried out (as described above) for each cell
type with compounds 1, 2, and 3 in the presence and absence of the maximum tolerated concentration
of metal salt.
Immunoﬂuorescence. Immunoﬂuorescence microscopy was carried out according to standard
protocols. Brieﬂy, 1  106 cells were ﬁxed in 1% formaldehyde in PBS and allowed to dry on coverslips.
Cells were permeabilized with 0.5% Triton X-100 in PBS, blocked with 50% FBS in PBS, and incubated with
a monoclonal mouse anti-Myc antibody (1:500; Source BioScience) and a polyclonal rabbit anti-GRASP
antibody (1:750; a kind gift from Graham Warren). Secondary anti-mouse Alexa Fluor 488 and anti-rabbit
Alexa Fluor 468 antibodies (Life Technologies) were used at 1:2,000 dilutions. Cells were mounted in
Vectashield (Vector Laboratories) containing the DNA counterstain DAPI (4=,6-diamidino-2-phenylindole).
Images were captured by using a Zeiss Axiovert 200M ﬂuorescence microscope and processed with
ZenPro (Zeiss).
Generation of an 8-HNT-resistant L. donovani cell line. Resistant lines were generated as de-
scribed previously (31), using compound 2 in L. donovani promastigotes. Starting at a sublethal
concentration of 1 M compound 2 in 3 independent cultures, concentrations were increased in a
stepwise manner. However, after a total of 270 days in culture, promastigotes were unable to grow in
10 M compound 2.
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Measurement of intracellular Zn2 levels in 8-HNT-treated L. donovani promastigotes and T.
brucei bloodstream forms. L. donovani promastigotes were grown to 2  107 cells ml1 and harvested
by centrifugation (10 min at 1,600  g). T. brucei bloodstream forms were grown to 2  106 cells ml1
and harvested by centrifugation (5 min at 800  g). Parasites were washed with PBS and resuspended
to a ﬁnal concentration of 2.5 107 parasites ml1 in fresh PBS. Cells were incubated with FluoZin-3 (ﬁnal
concentration, 5 M), pluronic acid (ﬁnal concentration, 5 M), and 14 mM glucose (T. brucei only).
Parasites were incubated for 60 min at room temperature (RT), washed three times with PBS, and then
resuspended in PBS (with 14 mM glucose for T. brucei only) before being aliquoted into a black,
clear-bottomed 96-well plate (ﬁnal concentration of 2.5  107 cells ml1). 8-HNT or control compounds
were added directly to cells, and ﬂuorescence was measured immediately by using a Pherastar ﬂuores-
cence spectrophotometer (excitation at 485 nm and emission at 520 nm). Calculations were performed
in Excel. Preliminary analysis conﬁrmed that 8-HNT compounds did not quench ﬂuorescence in the
absence of FluoZin-3. Parasites were conﬁrmed to be viable by microscopy after the completion of the
experiment.
Measurement of intracellular Zn2 levels in 8-HNT-treated human HepG2 cells. Prior to exper-
iments, HepG2 cells (1  104 cells per well) were plated into a 96-well plate and left overnight to adhere.
The following day, cells were washed twice with PBS and then incubated in 200 l PBS containing
FluoZin-3 (ﬁnal concentration, 5 M) and pluronic acid (ﬁnal concentration, 5 M) for 60 min at RT. Cells
were then washed three times with PBS prior to resuspension in 200 l PBS. Finally, cells were treated
with 100 M 8-HNT compounds or 8 M TPEN, and ﬂuorescence was measured immediately at an
excitation wavelength of 494 nm and an emission wavelength of 516 nm by using a Pherastar
ﬂuorescence spectrophotometer. Calculations were carried out in Excel.
Measurement of 8-HNT compound uptake. Mid-log-phase L. donovani promastigotes were treated
with and without compound 1 (5 M) for 30 min at 28°C or 4°C. Triplicate samples of the culture (2 
107 cells; 1 ml) were harvested by centrifugation at 16,000  g for 5 min. The supernatant (200 l) was
collected from each centrifuged sample, transferred to a fresh Eppendorf tube, and terminated by the
addition of 400 l acetonitrile (supernatant fraction). The remaining supernatant was discarded, and
acetonitrile (60 l) was added to each pellet fraction. Finally, 400 l acetonitrile was added to 200 l of
culture (equivalent of 4  106 cells) (total fraction). All fractions were then centrifuged at 16,000  g for
10 min and diluted as required with MilliQ water. All samples were analyzed in triplicate on a Waters
Acquity UPLC instrument coupled to a Waters micro TQs mass spectrometer. Chromatographic separa-
tion was achieved by using a Waters BEH (bridged ethylene hybrid) C18 column (1.7-m particle size, 2.1
by 50 mm), with a ﬂow rate of 0.6 ml min1, an injection volume of 0.2 l, and the following 2-min
gradient: 95% mobile phase A initially, with holding for 0.3 min before decreasing to 5% mobile phase
A over the next minute and holding for a further 0.49 min before returning to 95% mobile phase A.
Mobile phase A was water plus 0.1% formic acid, and mobile phase B was methanol plus 0.1% formic
acid. Cone voltage, collision energy, and MRM (multiple reaction monitoring) transition were optimized
at 50 V, 28 V, and 367.06  124.92 (parent ion transition to daughter ion), respectively, using the
automatic QuanOptimize feature. Additional MS parameters were as follows: positive electrospray
ionization, capillary voltage of 40 V, desolvation temperature of 500°C, source temperature of 150°C,
desolvation gas (nitrogen) at 1,000 liters/h, and cone gas (nitrogen) at 15 liters/h.
Fluorescence-based assay to determine the binding of zinc by 8-HNT compounds. ZnCl2 (5 M)
was incubated with various concentrations of our three 8-HNT compounds followed by the addition of
125 nM FluoZin-3 salt dye. Reaction mixtures were preincubated for 20 min at RT and then aliquoted into
a black 96-well plate. Fluorescence was then measured with a Pherastar spectrophotometer (excitation
at 485 nm and emission at 520 nm). Calculations were carried out in Excel.
Spectrophotometric assay to determine the stoichiometry for 8-HNT compounds binding to
divalent cations. UV-visible (UV-Vis) titrations were carried out essentially as described previously (65,
66). Aliquots of metal divalent cations (concentrated stocks were made initially in water and then diluted
in methanol) were added to a ﬁxed concentration of 50 M 8-HNT compound in methanol. After each
aliquot addition, the incubation mixture was left to stabilize for 5 min at 25°C prior to scanning.
Wavelength scanning was carried out at between 260 and 510 nm by using a UV-2401 PC UV-Vis
spectrophotometer (Shimadzu). For Job’s plot analyses (66), the combined concentration of 8-HNT and
cation was ﬁxed at 200 M, and only the molar ratio of cation versus 8-HNT compound varied. Changes
of the absorption at 475, 390, and 375 nm were indicative of cation complex formation with compounds
1 to 3, respectively. Speciﬁc absorbance at these wavelengths was determined and plotted against the
molar ratio of compound to cation to determine complex stoichiometry (66).
Accession number(s). The complete RIT-seq data sets reported in this paper have been depos-
ited in the European Nucleotide Archive (accession numbers PRJEB21478, PRJEB21479, and
PRJEB21480 for compounds 1 to 3, respectively). All other relevant data are within this paper and the
supplemental material.
SUPPLEMENTAL MATERIAL
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